Multicenter, Randomized, Phase III Study of a Single Dose of IncobotulinumtoxinA, Free from Complexing Proteins, in the Treatment of Glabellar Frown Lines

201367 citationsJournal Article

Authors

Alastair Carruthers

Jean Carruthers

William P. Coleman

Lisa Donofrio

Timothy C. Flynn

Michael H. Gold · Tennessee Clinical Research Center

Moritz Heinz · MerLion Pharma (Germany)

Laura Harrington

Derek Jones · Skin Care and Laser Physicians of Beverly Hills

David H. McDaniel

Abstract

A single dose of 20 U of incobotulinumtoxinA demonstrated efficacy and safety in the treatment of glabellar frown lines using new Food and Drug Administration efficacy variables.

Topics & Keywords

Botulinum Toxin and Related Neurological Disorders Venomous Animal Envenomation and Studies Pain Mechanisms and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Dermatologic Surgery

Volume 39, Issue 4, pp. 551-558

DOI: 10.1111/dsu.12100

Field-Weighted Citation Impact: 4.33